DocMorris Ltd
DOCM
ISIN CH0042615283 / Valor 4261528
DocMorris Ltd
UMushroom community rating:
About company
DocMorris Ltd is a prominent online pharmacy company that operates primarily in the European market. It specializes in providing a wide range of pharmaceutical products and health-related services directly to consumers through its digital platform. The company is known for its efficient distribution network, which ensures timely delivery of medications and health products. DocMorris leverages technology to enhance customer experience, offering services such as online consultations and personalized health advice. As a leader in the e-pharmacy sector, it continues to expand its offerings to include over-the-counter medications, prescription drugs, and wellness products, catering to the growing demand for convenient and accessible healthcare solutions.
Summarized from source with an LLMView SourceSector: HealthcareLatest Results (08.11.2025):
DocMorris Ltd's Half-Year Report 2025 shows strong momentum with notable revenue growth and improved EBITDA performance, particularly in the second quarter of 2025. The company reported increased external revenue, robust gains in its prescription (Rx) segment, and significant developments in digital healthcare services such as TeleClinic, all contributing to a strategic push toward sustainable profitability.
Revenue Performance
In the first half of 2025, DocMorris Ltd’s external revenue grew by 10.2% to CHF 572.1 million. The second quarter saw revenue rise by 7.1% to CHF 275.5 million despite fewer working days, underlining the strength of its sales performance.
Improved Q2 Earnings
While the adjusted EBIT-DA for the half-year stood at minus CHF 28.8 million, the report highlights a clear structural improvement in EBITDA during the second quarter, which signals a positive trend toward sustainable profitability as ongoing costs are spread across the year.
Rx Segment Growth
DocMorris Ltd’s Rx business experienced impressive growth, with external Rx revenue increasing by 43.5% in the first half of 2025 and an additional 4.6% boost from Q1 to Q2. This acceleration is expected to continue, driven by higher order frequencies and an increased basket value from existing customers.
Digital and Non-Rx Expansion
The non-Rx segment, including OTC business and services such as TeleClinic, grew by 4.4% in the first half of 2025. TeleClinic, in particular, saw a remarkable surge of over 150% to CHF 11.2 million, bolstering DocMorris Ltd's position in Germany's digital healthcare landscape.
Summarized from source with an LLMView SourceKey figures
Performance
Volatility
287 M
Market cap (USD)
250,276
Daily traded volume (Shares)
21.34 / 20.6
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
Alexander Priess
O H
Nadia Häring
EQUITIES OF THE SAME SECTOR
